ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Sanofi

Status and phase: Terminated; Phase 4

Conditions: Osteoporosis

Treatments: Drug: Risedronate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00544180

RISED_L_01686

Details and patient eligibility

About

To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.

Enrollment: 7 patients

Sex: Female

Ages: 55 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria :

• Postmenopausal ambulatory women
• Established osteoporosis

Exclusion criteria:

• History of cancer: basal cell or squamous cell carcinoma-documented 6-month remission,
• Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)